Innovations revealed at cancer conference

A range of discoveries that could change the way that cancers are targeted for treatment are being unveiled at a major UK conference.

Delegates at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool will hear about two studies by a team based at the University of Manchester, UK, that has developed a heat-sensitive cancer drug “grenade” that targets tumours directly.

The researchers have developed liposomes to carry drugs into cancer cells by fitting them with a heat-activated trigger.

Using mouse models, they found that by slightly heating tumours in the lab they could control when the cancer-killing ‘grenades’ release the drug and target the cancer.

Kostas Kostarelos, study author and professor of nanomedicine at the University of Manchester, said: “Temperature-sensitive liposomes have the potential to travel safely around the body while carrying your cancer drug of choice.

“Once they reach a ‘hotspot’ of warmed-up cancer cells, the pin is effectively pulled and the drugs are released. This allows us to more effectively transport drugs to tumours, and should reduce collateral damage to healthy cells.

“The thermal trigger is set to 42 degrees Celsius, which is just a few degrees warmer than normal body temperature. Although this work has only been done in the lab so far, there are a number of ways we could potentially heat cancer cells in patients – depending on the tumour type – some of which are already in clinical use.”

Delegates will also hear from Oxford University researchers who have discovered that mutations in gene SETD2 make cancer cells vulnerable to a drug that inhibits a protein called WEE1.

This is an Achilles heel of certain cancer cells, says study author, Dr Timothy Humphrey.

“Mutations in SETD2 are frequently found in kidney cancer and some childhood brain tumours, so we were excited when we discovered that a new drug we were studying specifically killed cancer cells with this mutation,” he said.

Dr Humphrey and his team showed that cancer cells with a mutated SETD2 gene were killed by a drug called AZD1775 after they exploited the concept of “synthetic lethality”, where a combination of two factors kills a cancer cell.

Co-author Dr Andy Ryan said: “When WEE1 was inhibited in cells with a SETD2 mutation, the levels of deoxynucleotides dropped below the critical level needed for replication. Starved of these building blocks, the cells die. Importantly, normal cells in the body do not have SETD2 mutations, so these effects of WEE1 inhibition are potentially very selective to cancer cells.”

• £635,000 has been committed by a collaboration of NCRI partners to a new initiative called Cellular Molecular Pathology (CM-Path), which aims to boost UK pathology research. The five-year initiative aims to boost the UK’s research activity in cellular molecular pathology.

It will be funded as a collaborative venture between ten of the NCRI partner organisations: Bloodwise, Breast Cancer Now, Cancer Research UK, the Chief Scientist Office (Scotland), the Department of Health (England), Health and Care Research Wales (Welsh Government), Health and Social Care (Northern Ireland), the Medical Research Council, Prostate Cancer UK and Tenovus Cancer Care.

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index